Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:SNSS
- CUSIP: 86732860
- Web: www.sunesis.com
Capitalization:- Market Cap: $47.97 million
- Outstanding Shares: 23,513,000
Average Prices:- 50 Day Moving Avg: $2.26
- 200 Day Moving Avg: $3.05
- 52 Week Range: $2.00 - $5.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.47
- P/E Growth: -0.01
Sales & Book Value:- Annual Revenue: $1.96 million
- Price / Sales: 24.47
- Book Value: ($0.27) per share
- Price / Book: -7.56
Profitability:- EBIDTA: ($34,640,000.00)
- Net Margins: -1,472.94%
- Return on Assets: -112.07%
Debt:- Current Ratio: 3.36%
- Quick Ratio: 3.36%
Misc:- Average Volume: 107,891 shs.
- Beta: 1.78
- Short Ratio: 5.5
Frequently Asked Questions for Sunesis Pharmaceuticals (NASDAQ:SNSS)
What is Sunesis Pharmaceuticals' stock symbol?
Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."
How were Sunesis Pharmaceuticals' earnings last quarter?
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) released its earnings results on Thursday, July, 27th. The company reported ($0.41) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.76) by $0.35. During the same quarter last year, the firm posted ($0.12) EPS. View Sunesis Pharmaceuticals' Earnings History.
When will Sunesis Pharmaceuticals make its next earnings announcement?
Where is Sunesis Pharmaceuticals' stock going? Where will Sunesis Pharmaceuticals' stock price be in 2017?
2 brokerages have issued 12 month price objectives for Sunesis Pharmaceuticals' shares. Their forecasts range from $3.00 to $3.00. On average, they expect Sunesis Pharmaceuticals' share price to reach $3.00 in the next twelve months. View Analyst Ratings for Sunesis Pharmaceuticals.
What are analysts saying about Sunesis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (8/24/2017)
- 2. Cantor Fitzgerald analysts commented, "Advancing Toward SNS-062 Data. SNSS has just begun enrolling patients in a Phase Ib study for SNS-062, which could have utility in ibrutinib-treated patients that develop a common resistance mutation (C481) and exploring the compound in CLL and other B-cell malignancies. Results from escalation cohorts could occur in 2Q18 (possibly ASCO, AACR), which could present a revaluation opportunity for the shares." (7/27/2017)
Who are some of Sunesis Pharmaceuticals' key competitors?
Some companies that are related to Sunesis Pharmaceuticals include aTyr Pharma (LIFE), Palatin Technologies (PTN), Tissue Regenix Group PLC (TRX), Eiger BioPharmaceuticals (EIGR), Zynerba Pharmaceuticals (ZYNE), ArQule (ARQL), Vernalis plc (VER), Brainstorm Cell Therapeutics (BCLI), CytRx Corporation (CYTR), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Navidea Biopharmaceuticals (NAVB), Galectin Therapeutics (GALT), Infinity Pharmaceuticals (INFI), ReNeuron Group Plc (RENE), Fibrocell Science (FCSC), OvaScience (OVAS) and Abzena PLC (ABZA).
Who are Sunesis Pharmaceuticals' key executives?
Sunesis Pharmaceuticals' management team includes the folowing people:
- Daniel N. Swisher Jr., President, Chief Executive Officer, Director
- Adam R. Craig M.D., Ph.D., Executive Vice President - Development, Chief Medical Officer
- James W. Young Ph.D., Non-Executive Independent Chairman of the Board
- Stephen B. Ketchum Ph.D., Director
- Geoffrey M. Parker, Director
- Steve R Carchedi, Independent Director
- Matthew K. Fust, Independent Director
Who owns Sunesis Pharmaceuticals stock?
Sunesis Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include
BALYASNY ASSET MANAGEMENT LLC
(9.32%), Balyasny Asset Management LLC (8.51%), NEA Management Company LLC (6.05%), Palo Alto Investors LLC (4.94%), DAFNA Capital Management LLC (3.62%) and Vanguard Group Inc. (2.58%). Company insiders that own Sunesis Pharmaceuticals stock include Dayton Misfeldt and Geoffrey M Parker. View Institutional Ownership Trends for Sunesis Pharmaceuticals.
Who sold Sunesis Pharmaceuticals stock? Who is selling Sunesis Pharmaceuticals stock?
Who bought Sunesis Pharmaceuticals stock? Who is buying Sunesis Pharmaceuticals stock?
Sunesis Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Virtu KCG Holdings LLC, Sphera Funds Management LTD., Vanguard Group Inc. and Wells Fargo & Company MN. Company insiders that have bought Sunesis Pharmaceuticals stock in the last two years include Dayton Misfeldt and Geoffrey M Parker. View Insider Buying and Selling for Sunesis Pharmaceuticals.
How do I buy Sunesis Pharmaceuticals stock?
Shares of Sunesis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sunesis Pharmaceuticals' stock price today?
One share of Sunesis Pharmaceuticals stock can currently be purchased for approximately $2.04.
MarketBeat Community Rating for Sunesis Pharmaceuticals (NASDAQ SNSS)MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Sunesis Pharmaceuticals (NASDAQ:SNSS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings |
| Consensus Rating: | Hold (Score: 2.00) |
| Consensus Price Target: | $3.00 (47.06% upside) |
Analysts' Ratings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/27/2017 | Cantor Fitzgerald | Reiterated Rating | Hold | $3.00 | Low |  |
| 11/3/2016 | Cowen and Company | Reiterated Rating | Hold | | N/A | |
| 7/29/2016 | Wells Fargo & Company | Upgrade | Market Perform -> Outperform | | N/A | |
(Data available from 9/20/2015 forward)
Earnings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)Earnings History by Quarter for Sunesis Pharmaceuticals (NASDAQ SNSS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | ($0.41) | | | | | N/A | |
| 7/27/2017 | Q2 2017 | ($0.76) | ($0.41) | $2.40 million | | View | N/A | |
| 5/8/2017 | Q1 2017 | ($0.83) | ($0.47) | $1.57 million | $0.67 million | View | Listen | |
| 3/9/2017 | Q4 2016 | ($0.43) | ($0.44) | $0.60 million | $0.68 million | View | Listen | |
| 11/3/2016 | Q316 | ($0.71) | ($0.62) | $0.60 million | $0.60 million | View | N/A | |
| 7/29/2016 | Q216 | ($0.10) | ($0.12) | $0.70 million | $0.60 million | View | Listen | |
| 5/5/2016 | Q116 | ($0.12) | ($0.12) | $0.77 million | $0.64 million | View | Listen | |
| 3/10/2016 | Q415 | ($0.14) | ($0.15) | $0.84 million | $0.67 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.12) | ($0.09) | $1.09 million | $0.68 million | View | Listen | |
| 7/30/2015 | Q215 | ($0.13) | ($0.15) | $1.21 million | $0.85 million | View | N/A | |
| 5/5/2015 | Q115 | ($0.16) | ($0.13) | $1.14 million | $0.90 million | View | Listen | |
| 3/12/2015 | Q414 | ($0.20) | ($0.02) | $1.17 million | $0.90 million | View | Listen | |
| 11/10/2014 | Q314 | ($0.17) | ($0.25) | $1.97 million | $0.85 million | View | Listen | |
| 8/5/2014 | Q214 | ($0.17) | ($0.20) | $1.32 million | $2.00 million | View | Listen | |
| 5/7/2014 | Q114 | ($0.17) | ($0.26) | $1.32 million | $2.00 million | View | Listen | |
| 3/6/2014 | Q413 | ($0.20) | ($0.15) | $1.37 million | $2.00 million | View | Listen | |
| 11/12/2013 | Q313 | ($0.20) | ($0.16) | $1.44 million | $1.99 million | View | Listen | |
| 7/29/2013 | Q2 2013 | ($0.21) | $0.18 | $1.22 million | $1.99 million | View | Listen | |
| 5/9/2013 | Q1 2013 | ($0.20) | ($0.23) | $0.75 million | $1.99 million | View | Listen | |
| 3/13/2013 | Q4 2012 | ($0.19) | ($0.20) | $0.32 million | $1.99 million | View | Listen | |
| 11/8/2012 | Q312 | ($0.11) | ($0.37) | $4.17 million | $0.26 million | View | N/A | |
| 8/9/2012 | | ($0.20) | ($0.20) | | | View | N/A | |
| 5/15/2012 | | ($0.18) | ($0.30) | | | View | N/A | |
| 11/14/2011 | | ($0.18) | ($0.11) | | | View | N/A | |
| 8/11/2011 | | ($0.15) | ($0.18) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Sunesis Pharmaceuticals (NASDAQ:SNSS)Current Year EPS Consensus Estimate: $-1.61 EPS
Next Year EPS Consensus Estimate: $-1.39 EPS
Dividend History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Sunesis Pharmaceuticals (NASDAQ:SNSS)Insider Ownership Percentage: 10.21%
Institutional Ownership Percentage: 57.54%
Insider Trades by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/9/2016 | Geoffrey M Parker | Director | Buy | 3,740 | $3.87 | $14,473.80 | |
| 5/26/2016 | Geoffrey M Parker | Director | Buy | 9,500 | $0.47 | $4,465.00 | |
| 5/25/2016 | Geoffrey M Parker | Director | Buy | 52,505 | $0.47 | $24,677.35 | |
| 12/21/2015 | Dayton Misfeldt | Director | Buy | 1,750,000 | $0.84 | $1,470,000.00 | |
| 8/25/2015 | Daniel N Swisher Jr | CEO | Buy | 12,216 | $1.01 | $12,338.16 | |
| 8/24/2015 | Daniel N Swisher Jr | CEO | Buy | 12,784 | $1.01 | $12,911.84 | |
| 8/29/2014 | Forest Baskett | Major Shareholder | Sell | 266,700 | $7.97 | $2,125,599.00 | |
| 8/28/2014 | Bay City Capital Llc | Major Shareholder | Sell | 300,700 | $7.98 | $2,399,586.00 | |
| 8/28/2014 | Dayton Misfeldt | Director | Sell | 200,000 | $7.89 | $1,578,000.00 | |
| 8/27/2014 | Adam R Craig | CMO | Sell | 2,554 | $8.00 | $20,432.00 | |
| 8/27/2014 | Daniel N Swisher Jr | CEO | Sell | 5,000 | $8.00 | $40,000.00 | |
| 8/27/2014 | Dayton Misfeldt | Director | Sell | 100,700 | $8.16 | $821,712.00 | |
| 8/27/2014 | Eric Bjerkholt | CFO | Sell | 10,000 | $8.00 | $80,000.00 | |
| 8/27/2014 | Krishna Kittu Kolluri | Major Shareholder | Sell | 108,300 | $8.17 | $884,811.00 | |
| 8/12/2014 | Dayton Misfeldt | Director | Sell | 743,700 | $6.64 | $4,938,168.00 | |
| 8/12/2014 | Equity Opportunities Fu Growth | Major Shareholder | Sell | 710,540 | $6.63 | $4,710,880.20 | |
(Data available from 1/1/2013 forward)
Headline Trends for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Latest Headlines for Sunesis Pharmaceuticals (NASDAQ:SNSS)
| Source: |
|
| Date | Headline |
|---|
 | Sunesis Pharmaceuticals (SNSS) Presents At 2017 Wells Fargo Healthcare Conference - Slideshow
seekingalpha.com - September 9 at 8:41 AM |
 | Sunesis Pharmaceuticals, Inc. (SNSS) Downgraded by ValuEngine
www.americanbankingnews.com - September 2 at 2:29 PM |
| Sunesis Pharmaceuticals: SNS-062 Could Be The Company's Salvation - Seeking Alpha
seekingalpha.com - August 31 at 10:17 AM |
 | Sunesis to Present at Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - August 31 at 10:17 AM |
 | Sunesis to Present at Upcoming Investor Conferences
finance.yahoo.com - August 31 at 10:17 AM |
| Sunesis Pharmaceuticals, Inc. (SNSS) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - August 27 at 4:22 PM |
| FY2017 EPS Estimates for Sunesis Pharmaceuticals, Inc. Increased by Cantor Fitzgerald (SNSS)
www.americanbankingnews.com - August 3 at 9:30 AM |
| Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - August 2 at 8:32 AM |
| Sunesis Pharmaceuticals' (SNSS) CEO Dan Swisher on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 1 at 4:03 PM |
 | Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial ... - Nasdaq
www.nasdaq.com - July 29 at 7:22 AM |
| Sunesis reports 2Q loss
finance.yahoo.com - July 28 at 8:09 AM |
| Edited Transcript of SNSS earnings conference call or presentation 27-Jul-17 6:00pm GMT
finance.yahoo.com - July 28 at 8:09 AM |
| Cantor Fitzgerald Reiterates "Hold" Rating for Sunesis Pharmaceuticals, Inc. (SNSS)
www.americanbankingnews.com - July 27 at 9:43 PM |
| Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Posts Earnings Results, Beats Expectations By $0.35 EPS
www.americanbankingnews.com - July 27 at 5:20 PM |
| Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights - GlobeNewswire (press release)
globenewswire.com - July 27 at 7:39 AM |
| Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights - GlobeNewswire (press release)
globenewswire.com - July 27 at 7:39 AM |
| Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - July 27 at 7:39 AM |
| Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - July 27 at 7:39 AM |
 | Sunesis to Host Conference Call on July 27th to Discuss Second Quarter 2017 Financial Results and Recent Highlights
feeds.benzinga.com - July 24 at 7:38 AM |
| Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK ... - GlobeNewswire (press release)
globenewswire.com - July 20 at 7:56 AM |
| Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - July 20 at 7:42 AM |
| Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies
finance.yahoo.com - July 18 at 8:48 PM |
| Sunesis Pharmaceuticals (SNSS) vs. Biohaven Pharmaceutical Holding Co (BHVN) Critical Analysis
www.americanbankingnews.com - July 17 at 9:55 AM |
| -$0.76 EPS Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter
www.americanbankingnews.com - July 6 at 7:36 AM |
| Sunesis Pharmaceuticals, Inc. (SNSS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - June 28 at 7:30 AM |
| Sunesis Pharmaceuticals Added to Russell Microcap® Index - GlobeNewswire (press release)
globenewswire.com - June 27 at 8:01 PM |
| Sunesis Pharmaceuticals Added to Russell Microcap® Index
finance.yahoo.com - June 27 at 8:30 AM |
 | Sunesis Pharmaceuticals (SNSS) Announces Presentation of ... - StreetInsider.com
www.streetinsider.com - June 24 at 6:51 AM |
| Sunesis Pharmaceuticals Announces Presentation of Updated Results from Washington University-Sponsored Phase 1/Cohort Expansion Trial of Vosaroxin Plus Azacitidine in Patients with MDS at the EHA Annual Meeting
finance.yahoo.com - June 24 at 6:51 AM |
| Analysts Expect Sunesis Pharmaceuticals, Inc. (SNSS) to Post -$0.76 EPS
www.americanbankingnews.com - June 12 at 8:30 AM |
| IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - May 20 at 5:35 AM |
| The Life Sciences Report Examines How Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug
finance.yahoo.com - May 19 at 10:01 AM |
| -$0.76 Earnings Per Share Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter
www.americanbankingnews.com - May 15 at 8:16 PM |
| Zacks Investment Research Upgrades Sunesis Pharmaceuticals, Inc. (SNSS) to Buy
www.americanbankingnews.com - May 13 at 11:16 PM |
| Edited Transcript of SNSS earnings conference call or presentation 8-May-17 6:00pm GMT
finance.yahoo.com - May 13 at 12:44 AM |
| Brokers Set Expectations for Sunesis Pharmaceuticals, Inc.'s FY2017 Earnings (SNSS)
www.americanbankingnews.com - May 12 at 12:32 PM |
| ETFs with exposure to Sunesis Pharmaceuticals, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 9:01 PM |
| Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 10:44 AM |
| Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights - GlobeNewswire (press release)
globenewswire.com - May 9 at 7:25 PM |
| Sunesis Pharmaceuticals, Inc. (SNSS) Releases Quarterly Earnings Results, Beats Expectations By $0.22 EPS
www.americanbankingnews.com - May 8 at 3:18 PM |
| Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - May 8 at 11:13 AM |
| Investor Network: Sunesis Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 8 at 11:13 AM |
 | Sunesis reports 1Q loss
marketbeat.com - May 8 at 7:06 AM |
| IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 4 at 8:16 PM |
 | INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Sunesis Pharmaceuticals, Inc. Investors
www.businesswire.com - May 3 at 11:07 PM |
| INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Sunesis Pharmaceuticals, Inc. Investors
finance.yahoo.com - May 3 at 11:07 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Sunesis Pharmaceuticals Inc.
finance.yahoo.com - May 3 at 6:05 PM |
| IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - May 3 at 6:05 PM |
| Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA)
www.nasdaq.com - May 3 at 10:45 AM |
| SUNESIS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Sunesis Pharmaceuticals Inc. To Contact The Firm
finance.yahoo.com - May 3 at 10:45 AM |
Sunesis Pharmaceuticals (SNSS) Chart for Wednesday, September, 20, 2017
